[HTML][HTML] Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant
…, A Lombard Koen, JJ Lombaard… - … England Journal of …, 2021 - Mass Medical Soc
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
[HTML][HTML] Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised …
…, G Kruger, DJ Kalonji, N Lalloo, JJ Lombaard… - The Lancet …, 2022 - thelancet.com
Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …
[HTML][HTML] Preexposure prophylaxis for HIV infection among African women
Background Preexposure prophylaxis with antiretroviral drugs has been effective in the
prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. …
prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. …
[HTML][HTML] Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection
…, C Brinson, P Philibert, J Lombaard… - … England Journal of …, 2020 - Mass Medical Soc
Background Long-acting injectable regimens may simplify therapy for patients with human
immunodeficiency virus type 1 (HIV-1) infection. Methods We conducted a phase 3, …
immunodeficiency virus type 1 (HIV-1) infection. Methods We conducted a phase 3, …
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3 …
Background Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …
[HTML][HTML] FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis
…, D Taylor, K Ahmed, K Agot, J Lombaard… - JAIDS Journal of …, 2014 - journals.lww.com
Background: Several clinical trials have demonstrated the safety and effectiveness of oral
tenofovir disoproxil fumarate (TDF), with or without emtricitabine (FTC), as pre-exposure …
tenofovir disoproxil fumarate (TDF), with or without emtricitabine (FTC), as pre-exposure …
[HTML][HTML] Effectiveness of the Ad26. COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B …
…, E Lazarus, A Nana, RM Maboa, P Kotze, J Lombaard… - The Lancet, 2022 - thelancet.com
Background We aimed to assess the effectiveness of a single dose of the Ad26.COV2.S
vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the …
vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the …
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy …
M Aboud, R Kaplan, J Lombaard, F Zhang… - The Lancet infectious …, 2019 - thelancet.com
Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non …
…, JJ Lombaard, M de Jager, JP Segorb, J Mallolas… - The lancet HIV, 2020 - thelancet.com
Background Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has
shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults …
shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults …
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP
…, M Wang, K Agot, K Ahmed, J Lombaard… - JAIDS Journal of …, 2014 - journals.lww.com
Background: FEM-PrEP was unable to demonstrate the effectiveness of oral emtricitabine/tenofovir
disoproxil fumarate (FTC/TDF) as pre-exposure prophylaxis for HIV prevention …
disoproxil fumarate (FTC/TDF) as pre-exposure prophylaxis for HIV prevention …